MEDP
Medpace Holdings, Inc.
MEDP has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MEDP overall, supported by stronger fundamentals and stronger valuation.
MEDP Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
MEDP's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MEDP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $493 | -25% |
| Fair | 34x | $611 | -7% |
| Forward | 34x | $657 | — |
| Current | 36x | $657 | — |
| Expensive | 42x | $748 | +14% |
Historical ranges are pointers, not guarantees.
MEDP's PE is in its fair range at 36x. If earnings grow as analysts expect, today's price would be 34x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over MEDP in the historical PE scenario, which offers more potential upside but is not a forecast.
MEDP Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for MEDP, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MEDP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.28 | +7% |
| Q3 2026 | $18.02 | +26% |
| Q2 2026 | $17.04 | +27% |
| Q1 2026 | $15.89 | +21% |
| Q4 2025 | $15.28 | +21% |
| Q3 2025 | $14.30 | +25% |
| Q2 2025 | $13.45 | +27% |
| Q1 2025 | $13.10 | +34% |
| Q4 2024 | $12.63 | +42% |
MEDP has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
MEDP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $716M | +8.5% |
| Q2 2026 | $707.3M | +17% |
| Q1 2026 | $706.6M | +27% |
| Q4 2025 | $708.5M | +32% |
| Q3 2025 | $659.9M | +24% |
| Q2 2025 | $603.3M | +14% |
| Q1 2025 | $558.6M | +9.3% |
| Q4 2024 | $536.6M | +7.7% |
MEDP's revenue has grown year over year every quarter since late 2020: $716M last quarter, up 8.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +1.6 points |
| Q2 2026 | 21% | -0.2 points |
| Q1 2026 | 20% | -0.3 points |
| Q4 2025 | 22% | -1.7 points |
| Q3 2025 | 21% | +0.4 points |
| Q2 2025 | 21% | +1 points |
| Q1 2025 | 20% | 0 points |
| Q4 2024 | 23% | +5.9 points |
MEDP has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MEDP on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
MEDP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $196.4M | -17% |
| Q2 2026 | $138.1M | -3% |
| Q1 2026 | $145M | +25% |
| Q4 2025 | $188.1M | +2.8% |
| Q3 2025 | $235.5M | +70% |
| Q2 2025 | $142.4M | +38% |
| Q1 2025 | $115.8M | -21% |
| Q4 2024 | $183M | +25% |
MEDP's free cash flow has been positive every quarter for seven years: $668M over the past year, down 1.4% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MEDP on cash flow, with more consistent year-over-year improvement.
MEDP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -182K shares |
| 1 year | -1.5% | -445K shares |
| 3 years | -11% | -3.4M shares |
| 5 years | -24% | -9.1M shares |
| Available history | -24% | -9.2M shares |
MEDP has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $294.8M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $4.6M |
| Q2 2025 | $540.9M |
| Q1 2025 | $371.9M |
| Q4 2024 | $169.9M |
MEDP spent $295M buying back its own shares over the past year, down 73% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MEDP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
MEDP has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over MEDP on leverage, with a lower net debt burden relative to earnings.
MEDP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 68.8 | Neutral |
MEDP's weekly RSI is 65 (neutral) and its Stochastic is 69 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MEDP PE vs Healthcare Sector
| Metric | MEDP | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 41% above |
| PE % | 65 | 29 | 36 pts above |
MEDP is trading at 36x earnings, a 41% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over MEDP on valuation relative to its sector.
MEDP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $635.0 | 3.4% above |
| 20 week MA | $603.7 | 8.8% above |
| 50 week MA | $538.6 | 22% above |
| 100 week MA | $466.3 | 41% above |
| 200 week MA | $384.2 | 71% above |
MEDP is in an uptrend: it's above all five of its weekly moving averages, and 71% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
MEDP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $83.7 | $139.1 | +66% |
| 2021 | $139.1 | $223.4 | +61% |
| 2022 | $223.4 | $212.7 | -4.8% |
| 2023 | $212.7 | $306.5 | +44% |
| 2024 | $306.5 | $341.1 | +11% |
| 2025 | $341.1 | $567.6 | +66% |
| 2026 YTD | $567.6 | $656.8 | +16% |
MEDP has finished higher in five of the last six years, three of them by more than 50%. It's up 16% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MEDP on returns for 2026, with the stronger performance.